A Phase 2 clinical study of lomab-B in patients with advanced AML or high-risk myelodysplastic syndrome (MDA) age 50 and older.
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2017
At a glance
- Drugs I-131-Apamistamab (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 21 Mar 2017 Results published in An Actinium Pharmaceuticals media release.
- 04 Jan 2017 New trial record